GS
ASND icon

GTS Securities’s Ascendis Pharma A/S ASND Stock Holding History

GTS Securities’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,000
Closed -$252K – 3829
2023
Q4 		$252K Sell
2,000
-5,300
-73% -$528K ﹤0.01% 3369
2023
Q3 		$684K Buy
+7,300
New +$683K ﹤0.01% 2312

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GTS Securities's ASND Position: Q1 2024 in Review

GTS Securities sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 4,316 shares — an estimated $544K sold.

GTS Securities first reported a position in ASND in Q4 2023 and held it in 1 quarter. The position peaked at $544K in Q4 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

  • GTS Securities reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
  • GTS Securities sold 4,316 Ascendis Pharma A/S shares in Q1 2024, an estimated $544K.
  • GTS Securities first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 1 quarter.
  • GTS Securities's Ascendis Pharma A/S position peaked at $544K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.